Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development

Ernest Beutler, Stephan Duparc, Ogobara Doumbo, Kanjaksha Ghosh, Marcus Vinicius Guimaraes De Lacerda, Didier Lapierre, Sornchai Looareesuwan, Zulfiqarali Premji, Tom Vulliamy, Christopher Whitty

Research output: Contribution to journalReview articlepeer-review

174 Citations (Scopus)


Glucose-6-phosphate dehydrogenase (G6PD) deficiency is relatively common in populations exposed to malaria. This deficiency appears to provide some protection from this infection, but it can also cause hemolysis after administration of some antimalarial drugs, especially primaquine. The risk of drug-induced G6PD deficiency-related hemolysis depends on a number of factors including the G6PD variant, the drug and drug dosage schedule, patient status, and disease factors. Although a great deal is known about the molecular biology of G6PD, determining the potential for drug-induced hemolysis in the clinical setting is still challenging. This report discusses the potential strategies for assessing drug-induced G6PD deficiency-related hemolytic risk preclinically and in early clinical trials. Additionally, the issues important for conducting larger clinical trials in populations in which G6PD deficiency is prevalent are examined, with a particular focus on antimalarial drug development.

Original languageEnglish
Pages (from-to)779-789
Number of pages11
JournalAmerican Journal of Tropical Medicine and Hygiene
Issue number4
Publication statusPublished - Oct 2007
Externally publishedYes


Dive into the research topics of 'Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development'. Together they form a unique fingerprint.

Cite this